Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (December 2012)
25 slides from Niagen Bioscience's investor presentation, Dec 5, 2012
Slide 1: ChromaDex 2012 Investor Presentation
©) ChromaDex 2012 Investor Presentation
Slide 2: Disclaimers
Disclaimers |2 dl Safe Harbor Ineahing of een ar ofthe secoteeActof 6532s amanda Sechondie othe Secures EachangeActot os, Forward todas efthe Crerewaboututrcovet.Satamertstatrenettatorannatreruchayourfiecal year 242 rctensorat ndutch my betaentedby the wet ‘eden amae “petra actrees cole“a-o henguive
Slide 3: The ChromaDex Mission
The ChromaDex: Mission l3 1 To acquire, develop, and commercialize novel, proprietary, early- stage Ingredient Technologies that address multi-billion-dollar markets Ingredient Technologies by leveraging a unique position as a y) To gain market intelligence and enable the identification of “recogniz
Slide 4: ChromaDex Discovers, Acquires, & Develops Early-stage Proprietary Ingredient Technologies
ChromaDex? Discovers, Acquires, & Develops Early-stage Proprietary Ingredient Technologies and Commercializes theml 4 in multi-billion-dollar markets Acquire Develop Commercialize 7 en iv se oe to Develop a differentiated Commercialize in multi-billion ee Discover novel, early-stage Acquire these In
Slide 5: Ingredient Technologies have commercialization opportunities in multi-billion-dollar markets
ChromaDex’s Ingredient Technologies have Is commercialization opportunities in multi-billion-dollar markets Ca Commercialization Opportunity In Ingredient Technology Size($) CAGR Licensing Dietary Supplements Functional Food & Beverage Animal Health Cosmeceuticals : q 6 9508+ e
Slide 6: Ingredient technology companies acquired at significant values
MARTEKO lie enriched: -») NEPTUNE QD Caneden avs Technology companies Patented vegetarian ‘omega-3 ingredient Fish Oil omega-3 Krill Oil omega-3 Probiotic technology Acquired by DSM for $1.08Bin 2010 Acquired by DSM for $550Min July 2012 Market cap $150-$250M Acquired by Schiff for $40M in 2011
Slide 7: ChromaDex's unique model gives it first-mover advantages
& ChromaDex’s unique model gives it protected, first-mover advantages in acquiring Ingredient Technologies ‘Aecees to Research, Insight to Consumer Markets... (Over250 University & Research Institution customers Over 1500 Industry Customers Q = PEPSICO ‘© Dartmouth Cornell University Stanford Univer
Slide 8: Legacy business is a revenue-generating platform with 13 years of expertise
. This advantage comes from the legacy business, a revenue- | it generating platform with 13 years of expertise in the natural Ca products industry Natural productfine chemicals Analytical & chemistry-based services ® Used forQA & R&D © $3.5M revenue in 2011 * Testing of products for identity, poten
Slide 9: Legacy business has established a portfolio of marquee customers
Over 13 years, ChromaDex’s legacy business has established a portfolio of marquee customers and Research Institutions FDA USDA @ ‘Dartmouth i Cornell University [TGF ww in QE verso @ HERBALIFE KRAFT. ESTEE LAUDER ©
Slide 10: The legacy standards & analytical services business is positioned for growth
The legacy standards & analytical services business is |10 positioned for growth t Increased consumer demand — natural products industry expected to reach $243B by 2015! t Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences. t Increased regulatory sc
Slide 11: Completed acquisition of Spherix Consulting
ChromaDex recently completed the acquisition of Spherix | Consulting, an entity with complementary regulatory & clinical capabilities © SPHERIX ist of Fortune 1000 customers Over25 years clinical & regulatory consulting experience Significant upsell and cross-sell opportunities Led by Claire Kruger,
Slide 12: ChromaDex has licensed proprietary Ingredient Technology from several sources
ye ChromaDexe has licensed proprietary Ingredient ssa Technology from several sources 12 Patent Pater pending Technology status + Cholesterleeduction (2) + Oxidative Stress maigaton USDA (ia Unversity of Misissipp) + Art-anstytweatment + Metabolic vascular, newrodegenerai (w grape extract) Cot (coim
Slide 13: Ingredient Technology is at various stages of development
ChromaDex? Ingredient Technology is at various stages 2 of development a Clinical Dietary Food & skin Supply Safety _Development Supplements Beverage Health __Care_ Pharma Ingredient = VV e#VeG@ 0 CO pler$Pure comple Gm malY Y¥ Oo © asi eB (ome) lone) ez] oo Next-generation products for mi
Slide 14: ChromaDex's model in action: pTeroPure case study
Discover Acquire @ ChromaDexe’s model in action — pTeroPure® case study \14 Commercialize 2008: Collaborates: 72003-2072: Obtains "2008; Partners with 2012: Partners ‘with USDA to provide exclusive access to USDA ‘manufacturerto achieve wth Glanbia to reference standards for research & begins ‘comme
Slide 15: pTeroPure pterostilbene IP-backed and clinically-studied brand
Blueberries contain the powerful antioxidant pterostilbene; ChromaDex? has developed and is monetizing its IP-backed & clinically-studied brand, pTeroPure® |15 plerPure pTeroPure® is ChromaDex-branded pterostilbene ® Pterostibene is a phytoalexin (plant defense system) found naturally in blueberries
Slide 16: pTeroPure evaluated in Phase 2/3 clinical study for lowering blood pressure
pTeroPure® was evaluated in a Phase 2/3 clinical study lie which showed statistically significant results for lowering blood pressure plersPure Clinicaltrial completed atthe University of Mississippi » Double-blind, randomized, placebo-controlled, IRB-reviewed * 80 patients, 4 arms. Eight-week durat
Slide 17: Monetization of pTeroPure is underway
. 4+@ Monetization of pTeroPure®is underway as channel » x " 17 bf expansion and uptake continues Doce Orn PLATINUM ** Organic Blueberry Granola bar '* Organic Date bar ea pleréPure Total Revenue $3.8M since 2009 launch otanvie™ ~~ Distnbution partner € >)
Slide 18: pTeroPure is the foundation ingredient in retail brand BluScience
pTeroPure?is the foundation ingredient in ChromaDexe’s 18 retail brand, BlUScience ¥ 1,8 s i BlaScience Bioscience Bluscience ®!4 BloSclence F asciencegs **@% ¢ TrimBlu EternalBla HeartBlu Memorysia BIU2GO Capsules and oral-dissolving melts 5 SKUs — anti-aging, heart-health, weight management, focus
Slide 19: Anthocyanins Overview
Overview + Anthocyanins are compounds responsible forthe deep purple color in berries, flowers, black rice and other botanicals + Specificanthocyanins have been studied more extensively and have ‘shown promising health benefits—e.g. cyanidin-3-glucoside("C3G”) Potential Health benefits + Weight Loss
Slide 20: Nicotinamide Riboside - In Development
* *6) Nicotinamide Riboside — In Development |20 Overview + Nicotinamide Riboside(NR) is a compound naturally foundin milk and shown to boost nicotinamide adenine dinucleotide (NAD) levels. NAD a critical compound that enables cells to convert fuel to energy + NR has potential to be a next-generatio
Slide 21: ChromaDex Highlights
First-mover Advantage ‘s A. l= === ChromaDexe Highlights la FocusedExpertise x ‘ChromaDey’s legacy standards & analytical services business continues to grow at a steady rate as it has over the last 13 years. Its expertise in the natural products industry gives the company a Unique platform of marke
Slide 22: ChromaDex At a Glance
ChromaDex At a Glance 22 « Founded 1999 by CEO, Frank Jaksch « Headquarters: Irvine, CA « Analytical Laboratory: Boulder, CO ~ Acquired in April 2003 from NaPro BioTherapeutics » Employees: Approximately 70 Irvine, CA Boulder, CO * Publicly-listed in 2008 * Symbol: CDXC «Total Shares Outstanding’ —
Slide 23: ChromaDex Management Team
ChromaDexe Management Team PA jakech % Founded ChromaDex in 1999 * Int Subsidies Manager at Phenomenex ‘= Expose in analytical chomstry, product davlopme * Recognized indsty expe, most recently appeanng ‘on Dateline NBC's Hansen Fes regarding ally {esting in the natural products industry * Board of
Slide 24: Shareholder Summary
Shareholder Summary Percent Shareholder Number of Shares oareshio! Dr: Phillip Frost 15,252,937 16.46% Opko Health, Inc. (NYSE:OPK) 1833333, 1.98% Frank L. Jaksch Jr (Founder, CEO, Director) 7,993,320 8.63% Other Directors and Officers 13,240,254 14.29% Total Insider Ownership 21,233,574 22.92% SUBT
Slide 25: Contact Information
Contact Information ChromaDex, Inc. 10005 Muirlands Bivd., Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0204 wwow.chromadex.com Investor Relations |25 Bob Prag, President The Del Mar Consulting Group, Inc. Phone: 858.794.9500 bprag@delmarconsulting.com ‘Scott Wilfong, President Al